Kura Oncology
#4614
Rank
$1.61B
Marketcap
United States
Country
Dr. Troy Edward Wilson J.D., Ph.D. (Chairman, CEO, Pres & Principal Financial Officer)
Dr. Marc Grasso M.D. (Advisor)
Ms. Kathleen Ford (Chief Operating Officer)
Summary
History
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of solid tumors, lymphoma and blood cancers. Kura was established in 2013 with the vision of developing novel, targeted therapies that will have a meaningful impact on the lives of patients in need. Our portfolio includes both small molecule and antibody therapies and includes pioneering molecularly targeted oncology programs targeting ALK, PI3K and SETD2.
Mission
Vision
Key Team
Mr. Thomas Doyle (Principal Accounting Officer & Sr. VP of Fin. and Accounting)
Mr. Pete De Spain (Sr. VP of Investor Relations & Corp. Communications)
Ms. Kirsten Flowers (Chief Commercial Officer & Chief Corp. Strategy Officer)
Dr. Stephen Dale M.D. (Chief Medical Officer)
Dr. Roger Bakale Ph.D. (VP and Head of CMC, Clinical & Commercial Manufacturing)
Mr. James E. Basta J.D., Esq. (Chief Compliance Officer & Corp. Sec.)
Ms. Teresa Brophy Bair Esq., J.D. (Chief Legal Officer & Corp. Sec.)
Recognition and Awards
References
Dr. Troy Edward Wilson J.D., Ph.D. (Chairman, CEO, Pres & Principal Financial Officer)
Dr. Marc Grasso M.D. (Advisor)
Ms. Kathleen Ford (Chief Operating Officer)